What is the main business of Inbio?

The main business activity of Inbio focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on October 17, 2018.

Where is the headquarters located?

The headquarters is located at: Plac Konstytucji 6, 00-550 Warszawa.

Who is on the management board?

The management board consists of: Michał Krawczyk (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 100,000 (approx. $27,012).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2020 to December 31, 2020.

What was the revenue?

In 2020, the company generated total revenue of $14,328.

No, the company recorded a net loss of $2,398 in 2020.

Which cost dominates operating expenses?

The largest operating cost category falls under external services. This category amounted to $16,574 in 2020, representing 99% of all operating expenses.

Inbiosp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2018-10-17

Share capital

100,000.00 PLN

Registered address

Plac Konstytucji 6/90c, 00-550 Warszawa, Poland

Financials

Filing timeliness

No financial statement for 2021 – the filing deadline has passed.

2021not filed
202030/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2020.

Results vs industry

Revenue

This companyUSD 14.33kMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD -2.40kMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 16.71kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 25.58kMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Michał Krawczyk – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Michał Krawczykage 36	99	$1,337.12	4.95%
Beata Teresa Strączyńska Krawczykage 64	1,780	$24,041.06	89%
Others	121	$1,634.25	6.05%

Beata Teresa Strączyńska Krawczyk and Michał Krawczyk hold a combined 94% – the ownership structure indicates family control.

Beneficial owners

Person	Rights

Bank accounts

Was a VAT taxpayer from 2018-10-24 to 2025-05-12.

Reason for removal: Art. 96 ust. 9a pkt 3 (VAT returns showing no transactions filed for 6 consecutive months or 2 quarters)

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Frontline BiosciencesS.A.	$219,186.29	frontlinebiosciences.com
AI Corelabsp. z o.o.	$128,365.55	aicorelab.com
ModicaP.S.A.	$103,400.72	modica.bio
WPD Pharmaceuticalssp. z o.o.	$90,822.78	wpdpharmaceuticals.com
WPD PharmaceuticalsS.A.	$87,561.70	wpdpharmaceuticals.pl
Stenocoatsp. z o.o.	$36,665.21	stenocoat.com
Platforma Badań Genetycznychsp. z o.o.	$28,558.39	zdrowegeny.pl
Bioselsp. z o.o.	$19,100.32	selol.pl
Omnisepticasp. z o.o.	$3,475.29	omniseptica.com
Wavex Energysp. z o.o.	$142.33	wavexenergy.com